Last updated: 2026-09-10 08:02:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NeuroSense Therapeutics Ltd. (NRSN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.37, with a market capitalization of $15.79M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.25 to $1.98. This page covers its latest market performance, valuation, price trends and company information.
$15.79M | |
$0.36 | |
$8.18 | |
$0.25 | |
$0.40 | |
968.00 | |
345.71K | |
-- | |
$1.98 | |
$0.25 | |
-- | |
-- |
NeuroSense Therapeutics Ltd. (NRSN) is trading at $0.37 in pre-market trading as of 2026-09-10 08:01:00, down 8.73% ($0.04) from the previous close of $0.40
Pre-market trading shows how investors are pricing NRSN before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, NeuroSense Therapeutics Ltd. (NRSN) moved from $0.43 to $0.37, representing a decline of 14.23% ($0.06).
The stock traded between $0.36 and $0.53 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 876.33 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.7%
NRSN is currently trading at $0.37, placing it 6.7% of the way from its 52-week low of $0.25 to its 52-week high of $1.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeuroSense Therapeutics Ltd. (NRSN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.